Haemonetics 

€69.5
15
+€0.5+0.72% Thursday 19:45

統計

當日最高
-
當日最低
-
52週最高
-
52週最低
-
成交量
-
平均成交量
-
市值
3.87B
市盈率
33.89
股息收益率
-
股息
-

即將到來

收益

7Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
0.72
0.84
0.95
1.07
預期每股收益
1.07
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 HAZ.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

106.14平均價格目標
最高估價為 €125。
來自過去 6 個月內的 7 個評級。這不是投資建議。
買入
57%
持有
43%
賣出
0%

關於

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Show more...
首席執行官
Mr. Christopher A. Simon
員工
3657
國家
US
ISIN
US4050241003
WKN
000881782

上市公司